AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 06:49:50 2024-04-30 am EDT			5-day change	1st Jan Change
1.89 ^SEK	-1.56%		-8.70%	-39.23%

Apr. 25	AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 10	Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	CI

Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).

April 09, 2024

Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (publ) (OM : ALZCUR) on April 10, 2024. Professor Jan Lundberg invests in the company and is proposed as a new member of the company's board of directors.

Jan Lundberg completed the acquisition of an unknown minority stake in AlzeCure Pharma AB (publ) (OM : ALZCUR) on April 10, 2024.

Latest news about AlzeCure Pharma AB

AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	Apr. 09	CI
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	Apr. 03	CI
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	Mar. 07	CI
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	Mar. 05	CI
AlzeCure Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
AlzeCure Pharma AB Announces Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators	Feb. 12	CI
AlzeCure Pharma AB Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference	Feb. 06	CI
AlzeCure Pharma AB Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain	Jan. 29	CI
AlzeCure Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
AlzeCure Pharma AB Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD	23-10-25	CI
Sweden's AlzeCure Pharma Gets Japanese Patent Approval for Alzheimer's Drug Candidate	23-10-19	MT
AlzeCure Pharma AB Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856	23-10-19	CI
Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference	23-10-12	CI
AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference	23-09-26	CI
AlzeCure Pharma AB Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference	23-09-20	CI
AlzeCure Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's	23-08-09	CI
AlzeCure Pharma AB Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders	23-07-11	CI
AlzeCure Pharma AB Announces New Article on Antidepressive Effects with NeuroRestore ACD856	23-07-03	CI
Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440	23-05-24	CI
AlzeCure Pharma AB Appoints Janet Hoogstraate to its Board	23-05-19	CI
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
AlzeCure Pharma AB Presents New Data At Alzheimer’s Conference AD/PD on the Potential Disease-Modifying Effect of Neurorestore ACD856	23-03-30	CI
Alzecure Achieves Last Patient Last Visit in Its Phase Ii Clinical Trial of the Non-Opioid Acd440 in Neuropathic Pain	23-03-13	CI

Chart AlzeCure Pharma AB

Duration

Period

More charts

Company Profile

AlzeCure Pharma AB is a Sweden-based pharmaceutical research and development company with a primary focus on Alzheimerâs disease and other brain disease indications. The Company develops five drug candidates within its two main research programs, NeuroRestore and Alzstatin. The drug candidates in NeuroRestore stimulate a central signaling pathway in the brain that is essential for the functioning of nerve cells and has a strong genetic link to cognitive disorders, such as Alzheimer's disease. The main drug candidate, ACD855, is an already approved veterinary medicine available for the treatment of central nervous system (CNS) indications in animals and has undergone preclinical trials for human indications of impaired cognitive disorders. Alzstatin focuses on reducing the production of toxic amyloid beta (AÎ²) protein in the brain. AÎ² plays a central role in the pathology of Alzheimerâs disease and starts to accumulate in the brain many years before the first symptoms are recognized.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALZECURE PHARMA AB	-39.23%	10.68M
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	102B
REGENERON PHARMACEUTICALS, INC.	+2.87%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-14.77%	21.4B
GENMAB A/S	-8.79%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-13.21%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	13.83B
SAREPTA THERAPEUTICS, INC.	+35.75%	11.97B

Bio Therapeutic Drugs

AlzeCure Pharma AB

Equities

ALZCUR

SE0010133785

Biotechnology & Medical Research

Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).

Latest news about AlzeCure Pharma AB

Chart AlzeCure Pharma AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs